Aduhelm’s Medicare woes leave questions about lofty premiums

Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. The approval of Biogen’s Aduhelm continues to have ripple effects across healthcare. Most recently, it’s rattled the payer landscape for Medicare, potentially triggering longer-term changes to how the government approaches payments for high-cost drugs. Last Friday, the … Read more

Two Key Questions About Payer Strategies in 2022

PM360 We asked experts in dealing with payers to tell us the optimal strategies for negotiating pricing and formularies and the continued push toward value-based models. Specifically, we wanted to know: What are the keys to successful payer-pharma negotiations in 2022? What data do payers most value from pharma? How are the other needs or … Read more

Medical regulator faces questions over board members’ links to drug firms | NHS

The UK medicines watchdog has been urged to strengthen its conflict of interest policy after it emerged that six of its board members are receiving payments from the pharmaceutical industry. Board members involved in overseeing the regulator’s “strategic direction” also have financial interests in companies including US and Saudi drug giants and firms with ambitions … Read more